Optimized Remission in Alcohol-related Liver Cirrhosis
Launched by COPENHAGEN UNIVERSITY HOSPITAL, HVIDOVRE · Mar 5, 2025
Trial Information
Current as of April 28, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "Optimized Remission in Alcohol-related Liver Cirrhosis," is studying ways to better understand and treat liver cirrhosis caused by alcohol use. The researchers aim to identify specific biological markers that can help predict how well a patient’s condition is improving or worsening. By focusing on the molecular changes in the liver, they hope to personalize treatment and improve outcomes for patients suffering from this serious condition.
To participate in the trial, individuals must have a confirmed diagnosis of alcohol-related liver cirrhosis and provide informed consent. Participants will receive standard care, which includes support for quitting alcohol and managing withdrawal symptoms. The trial will follow patients from their diagnosis until they either recover, pass away, or choose to leave the study. This research is crucial as it seeks to deepen our understanding of liver disease and inform better treatment options in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clinical suspicion of cirrhosis related to use of alcohol, supported by biochemistry and ultrasound or other imaging techniques.
- • Informed written consent.
- Exclusion Criteria:
- • The diagnosis of ALC is questioned with reasonable doubt.
- • Withdrawal of informed consent or no informed consent.
About Copenhagen University Hospital, Hvidovre
Copenhagen University Hospital, Hvidovre, is a leading clinical research institution in Denmark, renowned for its commitment to advancing medical knowledge and improving patient care. As a prominent academic hospital affiliated with the University of Copenhagen, it integrates cutting-edge research with clinical practice, fostering innovation in various medical fields. The hospital is dedicated to conducting rigorous clinical trials, ensuring adherence to ethical standards and regulatory guidelines, while prioritizing patient safety and welfare. With a multidisciplinary approach and access to diverse patient populations, Copenhagen University Hospital, Hvidovre plays a vital role in translating research findings into effective treatments and therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hvidovre, Capital Region, Denmark
Patients applied
Trial Officials
Nina Kimer, MD, PhD
Principal Investigator
Gastroenheden, Hvidovre Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported